Imricor Medical Systems (IMR) Q3 2025 TU earnings summary

Executive summary

• Achieved parallel regulatory submissions in the US for NorthStar and Vision-MR Diagnostic Catheter, both filed for 510(k) approval with the FDA.

• NorthStar received CE Mark and was commercially launched in Europe at quarter end, with strong initial demand.

• Identified a larger-than-expected installed base of cardiology-controlled MRI scanners in the US, supporting future clinical trial and commercial expansion.

• European sales pipeline grew from 26 to 35 hospitals during the quarter, with several deals progressing.

Financial highlights

• Cash receipts totaled $124k, temporarily reduced due to non-revenue-generating clinical trial enrollments.

• Net cash outflows from operating activities were $4.8 million, up 9% from Q2 CY25.

• Payments for operating costs were $5.5 million, up 2% from the prior quarter, mainly due to annual insurance premiums; adjusted operating costs decreased 6% to $5.1 million.

• Cash and short-term investments at quarter end were $45.7 million, down from $50.3 million at June 30, 2025.

• Cash and cash equivalents at September 30, 2025, were $38.3 million, with an additional $7.5 million in short-term investments.

Outlook and guidance

• Focus remains on driving adoption, expanding clinical trial footprint, and transforming cardiac ablation procedures globally.

• Key growth drivers include execution of VISABL-VT and VISABL-AFL trials, re-establishing the iCMR-guided atrial flutter ablation market in Europe, and expansion into Australia, New Zealand, and the Middle East.